Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Up 76.1% in May

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the target of a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 13,903 shares, an increase of 76.1% from the May 14th total of 7,893 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average trading volume of 24,005 shares, the short-interest ratio is presently 0.6 days.

Analyst Ratings Changes

Separately, Weiss Ratings cut Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Alaunos Therapeutics currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Alaunos Therapeutics

A hedge fund recently raised its stake in Alaunos Therapeutics stock. Geode Capital Management LLC grew its stake in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) by 25.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 19,736 shares of the company’s stock after buying an additional 3,945 shares during the period. Geode Capital Management LLC owned 0.85% of Alaunos Therapeutics worth $64,000 as of its most recent SEC filing. 27.72% of the stock is owned by institutional investors.

Alaunos Therapeutics Stock Up 0.9%

Shares of NASDAQ:TCRT opened at $2.30 on Tuesday. The company has a market cap of $56.17 million, a P/E ratio of -1.10 and a beta of -1.07. The business has a fifty day simple moving average of $2.62 and a 200-day simple moving average of $2.98. Alaunos Therapeutics has a 52 week low of $1.67 and a 52 week high of $6.20.

Alaunos Therapeutics (NASDAQ:TCRT) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.59) earnings per share (EPS) for the quarter.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.